Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

被引:121
作者
Andriole, GL
Humphrey, P
Ray, P
Gleave, ME
Trachtenberg, J
Thomas, LN
Lazier, CB
Rittmaster, RS
机构
[1] Univ Washington, Sch Med, Div Urol Surg, St Louis, MO 63110 USA
[2] Univ Washington, Sch Med, Div Urol, St Louis, MO 63110 USA
[3] Univ Washington, Sch Med, Div Pathol, St Louis, MO 63110 USA
[4] Univ Washington, Sch Med, Div Immunol, St Louis, MO 63110 USA
[5] Cook Cty Hosp, Div Urol, Chicago, IL USA
[6] GlaxoSmithKline, Res & Dev, Res Triangle Pk, NC USA
[7] Univ British Columbia, Div Urol, Vancouver, BC, Canada
[8] Univ Toronto, Div Urol, Toronto, ON, Canada
[9] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada
关键词
prostatic neoplasms; testosterone; 5-alpha-reductase; apoptosis;
D O I
10.1097/01.ju.0000136430.37245.b9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In the prostate testosterone is converted to dihydrotestosterone (DHT) by the enzymes 5alpha-reductase (5alphaR) types 1 and 2 (5aR1 and 5aR2). Suppression of DHT formation by 5aR inhibition may be beneficial in early treatment or prevention of prostate cancer. Although 5aR2 is the dominant enzyme in the prostate, evidence indicates that 5aR1 may be up-regulated in some prostate cancers. This suggests that dual inhibition of both isoenzymes may be more effective than suppression of 5aR2 alone in prostate cancer treatment or prevention. In this short-term pilot study we examined the effect of the dual 5aR inhibitor dutasteride on markers of tumor regression. Materials and Methods: A total of 46 men with clinically staged T1 or T2 prostate cancer were randomized to receive 5 mg per day of placebo or dutasteride for 6 to 10 weeks before radical prostatectomy. Resected tissues were analyzed to determine the effect of dutasteride on intraprostatic androgen levels, and indices of apoptosis and microvessel density (MVD) in malignant tissue, as well as degree of atrophy in benign tissue. Results: Treatment with dutasteride caused a 97% decrease in intraprostatic DHT and was associated with a trend toward increased apoptosis. In patients receiving dutasteride for 45 days or more, a significant increase in apoptosis and a trend toward decreased M-VD in prostate cancer tissue was observed. Dutasteride treatment was also associated with an 18% decrease in mean benign epithelial cell width compared with placebo (p <0.0001). Conclusions: In this pilot study dutasteride treatment resulted in almost complete suppression of intraprostatic DHT, increased apoptosis and a trend toward decreased M-VD. These findings suggest that short-term treatment with dutasteride can cause regression in some prostate cancers.
引用
收藏
页码:915 / 919
页数:5
相关论文
共 22 条
[1]   Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial [J].
Aus, G ;
Abrahamsson, PA ;
Ahlgren, G ;
Hugosson, J ;
Lundberg, S ;
Schain, M ;
Schelin, S ;
Pedersen, K .
BJU INTERNATIONAL, 2002, 90 (06) :561-566
[2]  
Bonkhoff H, 1996, PROSTATE, V29, P261, DOI 10.1002/(SICI)1097-0045(199610)29:4<261::AID-PROS7>3.0.CO
[3]  
2-E
[4]   KINETIC-PARAMETERS OF 5-ALPHA-REDUCTASE ACTIVITY IN STROMA AND EPITHELIUM OF NORMAL, HYPERPLASTIC, AND CARCINOMATOUS HUMAN PROSTATES [J].
BRUCHOVSKY, N ;
RENNIE, PS ;
BATZOLD, FH ;
GOLDENBERG, SL ;
FLETCHER, T ;
MCLOUGHLIN, MG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (04) :806-816
[5]   Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor [J].
Clark, RV ;
Hermann, DJ ;
Cunningham, GR ;
Wilson, TH ;
Morrill, BB ;
Hobbs, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (05) :2179-2184
[6]   Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice [J].
Connolly, JM ;
Rose, DP .
JOURNAL OF UROLOGY, 1998, 160 (03) :932-936
[7]   Differences in steroid 5α-reductase iso-enzymes expression between normal and pathological human prostate tissue [J].
Iehlé, C ;
Radvanyi, F ;
de Medina, SGD ;
Ouafik, L ;
Gérard, H ;
Chopin, D ;
Raynaud, JP ;
Martin, PM .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 68 (5-6) :189-195
[8]   PROSTATE VISUALIZATION STUDIES IN MALES HOMOZYGOUS AND HETEROZYGOUS FOR 5-ALPHA-REDUCTASE DEFICIENCY [J].
IMPERATOMCGINLEY, J ;
GAUTIER, T ;
ZIRINSKY, K ;
HOM, T ;
PALOMO, O ;
STEIN, E ;
VAUGHAN, ED ;
MARKISZ, JA ;
DEARELLANO, ER ;
KAZAM, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (04) :1022-1026
[9]   RESPONSE OF RAT AND HUMAN PROSTATIC CANCERS TO THE NOVEL 5-ALPHA-REDUCTASE INHIBITOR, SK-AND-F 105657 [J].
LAMB, JC ;
LEVY, MA ;
JOHNSON, RK ;
ISAACS, JT .
PROSTATE, 1992, 21 (01) :15-34
[10]   Inhibition of vascular endothelial growth factor in the treatment of solid tumors. [J].
Margolin K. .
Current Oncology Reports, 2002, 4 (1) :20-28